Đang chuẩn bị liên kết để tải về tài liệu:
Pharmaceutical Substances Syntheses, Patents, Applications - Part 205

Pharmaceutical Substances Syntheses, Patents, Applications - Part 205. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers. | Tiludronate disodium T 2041 H C CH-j CH3 I o 0 P 0 CH HjC n ch3 ch3 ch3 1. NoH DMF tetroisopropyl methyl enedi-phosphonote tetroisopropyl 4-chloro-phenylthio methylenedi-phosphonote 1 1. 12N oq. HCI 2. oq. NoOH HO P ONa II 0 Tiludronate disodium Reference s Ohnishi H. Nakamura T. Tsurukami H. Murakami H. Abe M. Barbier A. Bone Miner. BOM1ET 25 Suppl. 1 Abstr. 11 1994 . synthesis EP 100 718 Sanofi appl. 25.7.1983 F-prior. 29.7.1982 . monohydrate of the disodium salt EP582 515 Elf Sanofi appl. 3.8.1993 F-prior. 5.8.1992 . pharmaceutical preparations WO9 617 616 Sanofi appl. 5.12.1995 F-prior. 6.12.1994 . WO 9 641 618 Sanofi Winthrop appl. 4.6.1996 USA-prior. 8.6.1995 . pharmaceutical compositions WO9 530 421 Ciba-Geigy AG appl. 16.11.1995 GB-prior. 4.5.1994 . JP05 105 632 Meiji Seika Kaisha appl. 27.4.1993 J-prior. 6.6.1991 . EP 336 851 Sanofi appl. 11.10.1989 F-prior. 7.4.1988 . combinations with estrogenes for treatment of osteoporosis WO 9 214 474 Norwich Easton Pharmaceuticals appl. 3.9.1992 USA-prior. 26.2.1991 . WO 9 414 455 Merck Co. appl. 7.7.1994 USA-prior. 23.12.1992 . with parathyroid hormone for treatment of osteoporosis WO 9 607 418 Procter and Gamble Company appl. 14.3.1996 USA-prior. 9.9.1994 . WO 9 607 417 Procter and Gamble Company appl. 14.3.1996 USA-prior. 9.9.1994 . with growth hormone secretogogues for treatment of osteoporosis WO 9 511 029 Merck Co. appl. 27.4.1995 USA-prior. 19.10.1993 . Formulation s tabl. 200 mg 240 mg as sodium salt hemihydrate Trade Name s D Skelid Sanofi Winthrop F Skelid Sanofi Winthrop USA Skelid Sanofi 2042 T Timepidium bromide Timepidium bromide ATC A03 Use antispasmodic anticholinergic RN 35035-05-3 MF C17H22BrNOS2 MW 400.41 LD50 12 mg kg M i.v. 713 mg kg M p.o. 7 mg kg R i.v. 1213 mg kg R p.o. CN 3- di-2-thienylmethylene -5-methoxy-1 1 -dimethylpiperidinium bromide I.CHjOH HCI 5-bromo-nicotinic acid NaOH CuSO . Cu COOH 2. dimethyl sulfate CH i 3 MgBr thf 1. HCI 2. HjC Br ether .N. methyl N-meihyl-5-methoxynipecotate